Xcout Intel
Sonoma Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Sonoma Pharmaceuticals, Inc. among pharmaceuticals companies — ranked by similarity to what Sonoma Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Sonoma Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
Sonoma Pharmaceuticals, Inc. at a glance
Sonoma Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in Boulder, United States. It is publicly listed (SNOA) with a market capitalisation of $5.6M. Xcout tracks 9 named people at Sonoma Pharmaceuticals, Inc., including Amy Trombly (Chief Executive Officer, President & Director).
Sonoma Pharmaceuticals, Inc. leadership
- Amy TromblyChief Executive Officer, President & Director
- Jerome DvonchChief Financial Officer
- Arturo AngelSenior Vice President of Regulatory, Quality & Product Development
- Frederick J SandfordDirector
- James J SchutzDirector
- Jay E BirnbaumDirector
3 more named people on record for Sonoma Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Sonoma Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Sonoma Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. Its flagship product is Spryng, an intra-articular injection administered by veterinarians to effectively alleviate lameness and joint conditions, such as osteoarthritis, in canines and equines. The company's development pipeline further includes seventeen therapeutic devices poised for both veterinary and human clinical applications. Founded in 2009, PetVivo Holdings, Inc. maintains its corporate headquarters in Minneapolis, Minnesota.
Similar pharmaceuticals company
United-Guardian, Inc., operating both domestically and globally, specializes in the development, production, and distribution of a diverse range of cosmetic raw materials, pharmaceutical solutions, medical-grade lubricants, and proprietary industrial chemicals. Its extensive cosmetic ingredients catalog includes the LUBRAJEL line of water-based moisturizing and lubricating gel formulations, featuring variants such as LUBRAJEL NATURAL (derived from natural sources), LUBRAJEL MARINE, and LUBRASIL II SB (a silicone-infused LUBRAJEL formulation). Other key offerings in this category are LUBRAJEL II XD; B-122, a powdered lubricant suitable for pressed powders, eyeliners, blushes, and industrial uses; KLENSOFT, a surfactant for shampoos, shower gels, and makeup removers; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, and cleansers. For medical applications, United-Guardian provides lubricants like LUBRAJEL RR and RC, which are water-based gels specifically designed for urinary catheters. LUBRAJEL MG serves to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices. The company also offers LUBRAJEL LC and LUBRAJEL FA, specialized LUBRAJEL formulations tailored for oral care, alongside LUBRAJEL FLUID for lubricating various water-soluble products. The pharmaceutical portfolio features RENACIDIN, a prescription medication for preventing and dissolving calcifications in urethral catheters and the urinary bladder. Also included is CLORPACTIN WCS-90, an antimicrobial agent effective against infections in the urinary bladder, localized peritoneal infections, and infections affecting the eyes, ears, nose, throat, and sinuses. Industrial products comprise DESELEX, a sequestering and chelating agent vital for detergent manufacturing, and THOROCLENS, a powerful chlorine-based industrial cleaning solution. The firm also dedicates resources to research and development, primarily focusing on advancing cosmetic ingredients. Products are brought to market through a robust network of marketing partners, distributors, and wholesalers. Established in 1942, United-Guardian maintains its headquarters in Hauppauge, New York.
Similar pharmaceuticals company
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
Similar pharmaceuticals company
Sumitomo Pharma Co., Ltd. is a global company involved in the creation, production, and sale of a variety of products, including human pharmaceuticals, food ingredients and additives, and veterinary medicines. Its operations span across Japan, North America, China, and other international territories. The company's pharmaceutical offerings address a broad spectrum of medical needs. These include treatments for conditions such as Parkinson's disease, depression, type 2 diabetes, systemic fungal infections, hypertension, pruritus, chronic obstructive pulmonary disease (COPD), angina pectoris, and arrhythmia. Additionally, they manufacture atypical antipsychotics, antiepileptics, carbapenem antibiotics, gastrointestinal products, and specialized medications for Anderson-Fabry disease. Beyond healthcare, Sumitomo Pharma provides food components and enhancement agents like polysaccharides, along with savory flavorings such as soups and bouillons. The company also supplies chemical raw materials, which encompass pharmaceutical excipients, components for personal care products, substances used in coatings and industrial applications, and electronic materials. Moreover, it produces veterinary therapeutic solutions designed for domestic pets, specifically dogs and cats, as well as for various farm animals, including cattle, swine, poultry, horses, and cultivated fish. To drive innovation, Sumitomo Pharma fosters partnerships with several organizations. These collaborators include Healios K.K., Keio University, RIKEN, the Center for iPS Cell Research and Application, Kyoto University, and Aikomi Co., Ltd. The company also maintains a joint development agreement with SanBio Company Limited, a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., and a strategic alliance with Roivant Sciences Ltd. Originally established in 1897, the company, headquartered in Osaka, Japan, was known as Sumitomo Dainippon Pharma Co., Ltd. until it adopted its current name, Sumitomo Pharma Co., Ltd., in April 2022. It functions as a subsidiary of Sumitomo Chemical Company, Limited.
Similar pharmaceuticals company
Vetoquinol S.A. is a pharmaceutical company dedicated to animal health, responsible for researching, formulating, and distributing veterinary medicines and other health-related products throughout Europe, the Americas, and the Asia Pacific. The firm offers a comprehensive range of solutions for various therapeutic areas, including pain and mobility management, inflammatory conditions, dermatology, hygiene, parasite control, udder health, infectious diseases, reproductive care, behavioral issues, internal medicine, and cardiovascular-renal disorders. These products are developed for a diverse clientele of animals, encompassing livestock such as cattle, sheep, pigs, and poultry, alongside domestic dogs. Founded in 1933, Vetoquinol S.A. maintains its headquarters in Lure, France, and operates as a subsidiary of Soparfin SCA.
Veterinary Pharmaceuticals
Aurora Pharmaceutical, LLC develops, manufactures, and distributes veterinary pharmaceutical products and animal health solutions. The company serves livestock producers, veterinarians, and companion animal owners with a portfolio focused on parasite management, reproduction, wound care, and general health for cattle, swine, poultry, equine, and small animals.
Similar pharmaceuticals company
Headquartered in Tokyo, Japan, Seikagaku Corporation, established in 1947, specializes in the global development, manufacturing, and distribution of pharmaceuticals and medical devices, with a core focus on glycoconjugates. The company, which was formerly known as K.K. Seikagaku Kenkyusho until its name change in 1962, operates through two primary segments: Pharmaceuticals and LAL. Its product portfolio encompasses a range of therapeutic and surgical solutions. For joint health, Seikagaku provides intra-articular injections like ARTZ, ARTZ Dispo, VISCO-3, and SUPARTZ FX, designed to enhance joint function. The company also supplies ophthalmic surgical aids such as OPEGAN, OPEGAN Hi, and SHELLGAN, alongside MucoUp for endoscopic mucosal resection. Other notable offerings include Gel-One, a cross-linked hyaluronate hydrogel addressing knee osteoarthritis, and HERNICORE for lumbar disc herniation. Beyond finished products, Seikagaku is a supplier of bulk materials, specifically sodium hyaluronate and sodium chondroitin sulfate, which find application in various pharmaceutical and cosmetic formulations. Furthermore, the company develops and markets specialized endotoxin-detecting reagents, including Pyrochrome, ENDOSPECY, and TOXICOLOR, which are crucial for quality assurance in injectable pharmaceuticals, biological products, medical devices, manufacturing operations, and dialysate water quality. Its offerings also extend to oral care, featuring the KINUSUI Spray mouthwash. Seikagaku maintains a robust development pipeline, with promising candidates such as SI-6603 for lumbar disc herniation, SI-614 (a modified hyaluronate for dry eyes), SI-613 for osteoarthritis, SI-613-ETP targeting enthesopathy, and SI-449, a powdered adhesion barrier.
Similar pharmaceuticals company
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Healthcare & Pharmaceuticals
ActiMaris offers natural medical devices and solutions based on active singlet oxygen and sea salt to accelerate the healing of wounds, skin inflammation, and mucosal issues.
Similar pharmaceuticals company
Regenerex Pharma, Inc. provides advanced wound care solutions and products, including specialized sterile wound creams like Xcellderma and Accelerex, designed to treat chronic and acute wounds such as diabetic foot ulcers, pressure ulcers, and burns. The company serves healthcare systems, managed care organizations, and federal agencies by offering turnkey wound closure programs and patented technology aimed at improving healing outcomes and managing treatment costs.
Similar pharmaceuticals company
Virbac provides a comprehensive range of products, vaccines, parasiticides, diagnostics, and services for veterinarians, farmers, and pet owners globally. The company focuses on animal health and care for both companion animals and farm species such as cattle, aquaculture, and swine.
Similar pharmaceuticals company
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Sonoma Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Sonoma Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →